Featured Topics
Calendar

November 12, 2024

Q3 2024 Results / Quarterly Statement

March 05, 2025

FY/Q4 2024 Results / Annual Report
Sustainability Report 2024
Press Releases
Share Price / Index
September 16, 2024
Not intended for U.S. and UK Media – Data from ARANOTE trial presented as a late-breaking oral presentation at the 2024 ESMO Congress:
Darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with mHSPC
September 10, 2024
Not intended for UK Media – Late-breaking data from Phase III long-term study OASIS 3 presented at 2024 TMS Annual Meeting:
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
September 10, 2024
Not intended for U.S. and UK Media – Late-breaking data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024
New subgroup analysis from FINEARTS-HF revealed patients with heart failure and a left ventricular ejection fraction of ≥40% receiving finerenone had a reduced risk of new-onset diabetes

Our Products

Our broad product portfolio includes many world-famous brands that have shaped our Bayer brand. With our products, we are helping to find solutions to some of the greatest challenges of our time. So that health and nutrition can be made available to everyone.